Project Grant R01CA307225
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $545K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85724, USA
Similar Awards
- Federal Grant Award Summary New York University School of Medicine received a $585,482 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year research award supports fundamental investigations into the molecular mechanisms of breast cancer metastasis, specifically examining the dual role of the translation factor DAP5 (Death-Associated Protein 5) in selective messenger RNA...
- Federal Grant Award Summary Albany Medical College received a $648,579 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective June 1, 2026 through May 31, 2031. The grant supports research investigating the role of tumor biomechanics on drug-receptor engagement, specifically examining how extracellular matrix (ECM) stiffness, collagen density, and vascular dysfunction influence monoclonal antibody (MAb)...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $930,500 under the Cancer Biology Research program (CFDA 93.396) to the University of Arizona to support a seven-year project (September 10, 2025 – August 31, 2032) investigating loss of Y chromosome (LOY) in cancer development and progression. The research focuses on understanding why loss of the Y chromosome in both cancer cells and immune cells within the tumor microenvironment drives aggressive bladder cancer...
- Federal Project Grant Award Summary The University of Illinois received a $565,909 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. This award funds fundamental research investigating microcalcifications (MCs) in breast cancer through the development and application of engineered mineralized hydrogels that replicate the tumor microenvironment (TME). The research addresses a critical gap...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $1.056 million to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to support research on overcoming resistance to targeted therapies in breast cancer. Initiated August 20, 2025, and extending through July 31, 2032, this project delivers fundamental and applied research aimed at understanding and addressing the development of drug resistance in...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $627,371 project grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded on June 23, 2025, with an expected completion date of May 31, 2030. This award supports research focused on overcoming treatment resistance in estrogen receptor-positive (ER+) breast cancer through targeted degradation of cyclin-dependent kinases 4 and 6 (CDK4/6). The...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of South Alabama $733,494 under the Cancer Biology Research program (CFDA 93.396) on July 7, 2025, to investigate intercellular transfer of mitochondria at the nerve-cancer interface and its role in breast cancer metastasis. The project, which extends through May 31, 2030, will develop and utilize MitoTracer, an innovative lineage-tracing genetic strategy that enables permanent labeling of cancer cells...
- Federal Project Grant Award Summary The National Cancer Institute awarded The University of Texas Southwestern Medical Center a Cancer Treatment Research grant (CFDA 93.395) in the amount of $426,828 on May 4, 2026, with a project completion date of April 30, 2028. This project grant funds research to validate and translate discoveries regarding JUMONJI KDM5 histone demethylase enzymes as therapeutic targets for estrogen receptor-positive breast cancers that have developed resistance to CDK4/6...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Maryland, Baltimore a $2.84M Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate improved cancer treatment methodologies. The award, effective August 18, 2025 through July 30, 2029, funds research focused on enhancing the therapeutic efficacy of cyclophosphamide (CPA) and doxorubicin (DOX)-based chemotherapy regimens while minimizing treatment-related toxicity....
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 24, 2025, with completion scheduled for August 31, 2029. This award supports fundamental research investigating the mechanisms and impact of Neuregulin 3 (NRG3) induction in bone metastasis of breast cancer. The project will employ molecular and genetic approaches to...